Naltrexone come trattamento off-label delle compulsività in pazienti con disturbi del neurosviluppo: descrizione di due casi clinici

Journal title MISSION
Author/s N. Marsetti, L.S. Novel, M. Campana
Publishing Year 2026 Issue 2026/74
Language Italian Pages 3 P. 44-46 File size 0 KB
DOI 10.3280/mis74-2026oa23273
DOI is like a bar code for intellectual property: to have more infomation click here

View article Download Open Access article

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Introduction: Naltrexone is an opioid receptor antagonist approved for the treatment of alcohol and opioid use disorder. It has been explored off-label for the modulation of compulsive behaviors and impulse control.
In autism spectrum disorders (ASD), controlled studies have not shown consistent benefits on core symptoms; instead, heterogeneous results have been reported on associated behavioral manifestations.
Case presentation: We report two cases.

Conclusions: In selected patients with neurodevelopmental disorders and clinically significant compulsivity, naltrexone may be an off-label, symptom-targeted adjunct option; prospective studies with standardized measures are needed.

Keywords: Naltrexone;Autism spectrum disorder;Intellectual disability;Adult ADHD;Binge eating;Compulsive sexual behavior;compulsivity;Off-label treatment

  1. Soutschek A., Weber S.C., Kahnt T., Quednow B.B., Tobler P.N. (2019). Opioid antagonism reduces wanting by dampening striatal reward signals. J Neurosci., 39: 8040-8050.
  2. Campbell M., Anderson L.T., Small A.M. et al. (1993). Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry., 32: 1283-1291.
  3. Willemsen-Swinkels S.H., Buitelaar J.K., van Engeland H. (1995). The effect of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry., 37: 806-812.
  4. Willemsen-Swinkels S.H., Buitelaar J.K., Nijhof G.J., van Engeland H. (1996). Failure of naltrexone to reduce self-injurious and autistic behavior in mentally retarded adults. Arch Gen Psychiatry., 53: 151-158.
  5. Roy A., Roy M., Deb S., Unwin G. (2015). Are opioid antagonists effective in reducing self-injurious behavior in adults with intellectual disability? A systematic review. J Intellect Disabil Res., 59: 55-67.
  6. Fang Y.Y., Chen C.X., Zhang Y. et al. (2020). Opioid antagonists in the treatment of binge eating disorder: a meta-analysis. Psychiatry Res., 284, 112681.
  7. Bostwick J.M., Bucci J.A. (2008). Internet sex addiction treated with naltrexone. Mayo Clin Proc., 83: 226-230.
  8. Kraus S.W., Meshberg-Cohen S., Martino S., Quinones L.J., Potenza M.N. (2015). Treatment of compulsive pornography use with naltrexone: a case report. Am J Psychiatry., 172: 1260-1261.
  9. Savard J., Sabourin S., Lesage A. (2020). Naltrexone in the treatment of compulsive sexual behavior disorder: a feasibility study. J Sex Med., 17: 735-745.
  10. Grant J.E., Odlaug B.L., Kim S.W. (2010). Naltrexone treatment of pathological gambling and other impulse control disorders. CNS
  11. Drugs., 24: 561-573.

N. Marsetti, L.S. Novel, M. Campana, Naltrexone come trattamento off-label delle compulsività in pazienti con disturbi del neurosviluppo: descrizione di due casi clinici in "MISSION" 74/2026, pp 44-46, DOI: 10.3280/mis74-2026oa23273